Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.695 USD | +0.47% | +0.79% | -43.07% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.07% | 1.54B | |
+64.52% | 62.59B | |
-1.31% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.49% | 26.21B | |
-21.66% | 19.09B | |
+4.85% | 13.08B | |
+25.57% | 12.26B | |
+28.14% | 12.05B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk